Hematologic Oncology

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Sagar Lonial, MD, FACP, discusses the updated data from DREAMM-2 with belantamab mafodotin, associated toxicities to be aware of, and future directions for research.

Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

Paul G. Richardson, MD, discusses the next steps ​with the investigational cereblon E3 ligase modulator agent CC-92480 research in ​relapsed/refractory multiple myeloma.

Courtney DiNardo, MD, MSCE, discusses the rational​e for a pooled analysis evaluating venetoclax in acute myeloid leukemia.

Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.

During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.

John Kuruvilla, MD, FRCPC, discusses the safety of pembrolizumab (Keytruda) versus brentuximab vedotin in classical Hodgkin lymphoma.

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

The recent approval of selinexor (Xpovio) provides a novel treatment for patients with diffuse large B-cell lymphoma who have exhausted available options.

Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.

Nilanjan Ghosh, MD, PhD, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B-cell non-Hodgkin lymphoma.

The combination of the antibody­-drug conjugate loncastuximab tesirine and ibrutinib showed early clinical activity with manageable toxicity in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

The FDA has lifted a partial clinical hold that had been placed on the phase 2 TELLOMAK trial, which is examining the safety and efficacy of lacutamab in patients with advanced T-cell lymphoma.

Caron Jacobson, MD, discusses the initial ZUMA-5 findings and the next steps with axicabtagene ciloleucel in follicular lymphoma and marginal zone lymphoma.

John Kuruvilla, MD, FRCPC, discusses the broad utility of pembrolizumab in Hodgkin lymphoma.

Brian T. Hill, MD, PhD, discusses the safety profile of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.

A supplemental new drug application has been submitted to the FDA for review for the use of ibrutinib in combination with rituximab as a treatment for patients with Waldenström macroglobulinemia.

In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.